SGLT inhibitors in management of diabetes

Keyphrases

• Diabetes Management 100%
• Sodium-glucose Cotransporter Inhibitors 100%
• SGLT1 100%
• Kidney 66%
• Type 2 Diabetes Mellitus (T2DM) 66%
• Glucose-lowering Drugs 66%
• Sodium-glucose Cotransporter 66%
• Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i) 66%
• Reabsorption 66%
• Clinically Significant 33%
• Type 1 Diabetes Mellitus (T1DM) 33%
• Insulin 33%
• Weight Loss 33%
• Gastrointestinal 33%
• Hyperglycemia 33%
• Blood Pressure 33%
• Low Risk 33%
• Monotherapy 33%
• Mechanism of Action 33%
• Hypoglycemia 33%
• Insulin Independence 33%
• Insulin Therapy 33%
• Patients with Diabetes 33%
• Natural History 33%
• New Drug Targets 33%
• Type I Diabetes 33%
• Blood Glucose Reduction 33%
• Small Intestine 33%
• Renal Glucose 33%
• Dapagliflozin 33%
• Glomerular Filtration 33%
• Genital Infection 33%
• Urinary Tract Infection 33%
• SGLT2 Inhibition 33%
• Renal Elimination 33%
• Canagliflozin 33%
• Randomized Clinical Trial 33%
• Empagliflozin 33%
• Intestinal Glucose Absorption 33%

Medicine and Dentistry

• Diabetes 100%
• Sodium Glucose Cotransporter Inhibitor 100%
• Maturity Onset Diabetes of the Young 66%
• Sodium Glucose Cotransporter 66%
• Urinary Excretion 33%
• Monotherapy 33%
• Blood Pressure 33%
• Hypoglycemia 33%
• Hyperglycemia 33%
• Insulin Treatment 33%
• Blood Glucose 33%
• Insulin Dependent Diabetes Mellitus 33%
• Dapagliflozin 33%
• Patient with Diabetes 33%
• Glomerulus Filtration 33%
• Genital Tract Infection 33%
• Urinary Tract Infection 33%
• Gastrointestinal Distress 33%
• Empagliflozin 33%
• Randomized Clinical Trial 33%
• Canagliflozin 33%
• Glucose Absorption 33%
• Small Intestine 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Sodium Glucose Cotransporter Inhibitor 100%
• Non Insulin Dependent Diabetes Mellitus 66%
• Elimination 66%
• Sodium Glucose Cotransporter 66%
• Hyperglycemia 33%
• Monotherapy 33%
• Hypoglycemia 33%
• Dapagliflozin 33%
• Insulin Dependent Diabetes Mellitus 33%
• Urinary Tract Infection 33%
• Genital Tract Infection 33%
• Randomized Clinical Trial 33%
• Gastrointestinal Symptom 33%
• Canagliflozin 33%
• Empagliflozin 33%